The Excess Cost of Acute Exacerbations of Chronic Bronchitis in Patients Aged 45 and Older in England and Wales

McGuire, Alistair; Irwin, Debra E.; Fenn, Paul; Gray, Alastair; Anderson, Pippa; Lovering, A. M.; MacGowan, Alasdair

doi:10.1046/j.1524-4733.2001.45049.x

Cited by 48 publications

(35 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, the true cost of a disease is measured by the additional burden imposed by that disease on society. This additional burden takes the form of increased resource utilisation by breast cancer patients, which exceeds the use of resources by the general population [12]. Therefore, a case-control study design was used to compare total costs of breast cancer patients with costs of an equivalent standardised population with a view to calculating the additional costs that can be attributed to breast cancer.…”

Section: Methodsmentioning

confidence: 99%

The costs of breast cancer prior to and following diagnosis

et al. 2010

View full text Add to dashboard Cite

This retrospective incidence-based cost-of-illness analysis aims to quantify the costs associated with female breast cancer in Flanders for the year prior to diagnosis and for each of the 5 years following diagnosis. A bottom-up analysis from the societal perspective included direct health care costs and indirect costs of productivity loss due to morbidity and premature mortality. A case-control study design compared total costs of breast cancer patients with costs of an equivalent standardised population with a view to calculating the additional costs that can be attributed to breast cancer. Total average costs of breast cancer amounted to 107,456 per patient over 6 years. Total costs consisted of productivity loss costs (89% of costs) and health care costs (11% of costs). Health care costs did not vary with age at diagnosis. Health care costs of breast cancer patients converged with those of the general population at 5 years following diagnosis. Patients with advanced breast cancer stadia had higher health care costs. Cost estimates provided by this analysis can be used to determine priorities for, and inform, future research on breast cancer. In particular, attention needs to be focussed on decreasing productivity loss from breast cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

The costs of breast cancer prior to and following diagnosis

et al. 2010

View full text Add to dashboard Cite

show abstract

“…KEYWORDS: a 1 -antitrypsin deficiency, chronic obstructive pulmonary disease, health status, respiratory tract infections E xacerbations of chronic obstructive pulmonary disease (COPD) place a significant burden on healthcare resources and expenditure [1]. Furthermore, exacerbations adversely affect patients and more frequent exacerbations have been shown to be related to worse quality of life (QoL) [2].…”

mentioning

confidence: 99%

Exacerbations in α₁-antitrypsin deficiency

Needham

Stockley²

2005

Eur Respir J

View full text Add to dashboard Cite

This study aimed to investigate the nature and effect of exacerbations in patients with a 1 -antitrypsin deficiency and to assess the impact of exacerbations on health status. Furthermore, the relationship of exacerbations to changes in lung function and health status was investigated.In total, 265 patients with severe deficiency (PiZ phenotype) were assessed over 12 months and a subgroup of 87 patients was studied for 3 yrs. Exacerbations were recorded and patients underwent full lung function testing and health status measurement.Exacerbations occurred in 142 patients (54%) over 12 months, with a median duration of 14 days (interquartile range 7-21). Health status was significantly worse in patients with exacerbations, especially those with frequent exacerbations. Neither the presence nor the frequency of exacerbations showed a relationship to decline in forced expiratory volume in one second, but the number of exacerbations was weakly associated with decline in gas transfer of the lung for carbon monoxide. Despite lung function decline, health status did not change significantly over 3 yrs.In conclusion, exacerbations occur commonly in patients with a 1 -antitrypsin deficiency and are associated with worse health status. Exacerbations were associated with a decline in the gas transfer of the lung for carbon monoxide over time, but show no relationship to changes in forced expiratory volume in one second. Despite lung function decline, patients do not show a progressive loss in health status.

show abstract

“…Ideally, the true cost of a disease is measured by the additional burden imposed by that disease on society. This additional burden takes the form of increased resource utilisation by endometriosis patients, which exceeds the use of resources by the general population [19]. For this purpose, a case-control study design can be used to compare total costs of endometriosis patients with costs of an equivalent standardised population with a view to calculating the additional costs that can be attributed to endometriosis.…”

Section: Discussionmentioning

confidence: 99%

Endometriosis Cost Assessment (the EndoCost Study): A Cost-of-Illness Study Protocol

Simoens

Hummelshøj

Dunselman

et al. 2010

Gynecol Obstet Invest

View full text Add to dashboard Cite

Aims: The EndoCost study aims to calculate the costs of endometriosis from a societal perspective. Methods: This multicentre, prevalence-based cost-of-illness analysis aggregates data on endometriosis costs and quality of life from a prospective hospital questionnaire and from both retrospective and prospective patient questionnaires. The EndoCost study comprises 12 representative tertiary care centres involved in the care of women with endometriosis in 10 countries. The sample includes patients with a laparoscopic and/or histological diagnosis of endometriosis and with at least 1 patient contact related to endometriosis during 2008. The EndoCost study measures direct healthcare costs (e.g. costs of medication, physician visits), direct non-healthcare costs (e.g. transportation costs), and indirect costs of productivity loss. Cost questions are developed specifically for the purpose of the EndoCost study. Quality of life is measured using the EuroQol-5D and relevant parts of the Global Study of Women’s Health instruments. Both aggregate analyses and country-specific analyses are planned for total costs per patient. Costs are broken down into cost drivers and into the various payers that incur costs. Conclusions: The cost estimates provided by the EndoCost cost-of-illness analysis may be used to justify the prioritisation of future research in endometriosis.

show abstract

The Excess Cost of Acute Exacerbations of Chronic Bronchitis in Patients Aged 45 and Older in England and Wales

Abstract: These results suggest that improving the management of AECB with the objective of reducing the number of AECB treatment failures and the associated hospital admissions could significantly reduce expenditures by the UK NHS.

Cited by 48 publications

References 5 publications

The costs of breast cancer prior to and following diagnosis

The costs of breast cancer prior to and following diagnosis

Exacerbations in α₁-antitrypsin deficiency

Endometriosis Cost Assessment (the EndoCost Study): A Cost-of-Illness Study Protocol

Contact Info

Product

Resources

About

The Excess Cost of Acute Exacerbations of Chronic Bronchitis in Patients Aged 45 and Older in England and Wales

Abstract: These results suggest that improving the management of AECB with the objective of reducing the number of AECB treatment failures and the associated hospital admissions could significantly reduce expenditures by the UK NHS.

Cited by 48 publications

References 5 publications

The costs of breast cancer prior to and following diagnosis

The costs of breast cancer prior to and following diagnosis

Exacerbations in α1-antitrypsin deficiency

Endometriosis Cost Assessment (the EndoCost Study): A Cost-of-Illness Study Protocol

Contact Info

Product

Resources

About

Exacerbations in α₁-antitrypsin deficiency